Varian has secured an investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a clinical trial of FLASH therapy is an experimental treatment modality designed to deliver radiation therapy at ultra-high dose rates.
With ultra-high dose rates, FLASH therapy is said to be delivered in less than one second and more than 100 times faster compared to conventional radiation therapy.
The study, which is named as FAST-01(feasibility study of FLASH radiotherapy for the treatment of symptomatic bone metastases), will include the investigational use of Varian’s ProBeam particle accelerator that is modified to deliver an advanced non-invasive treatment option for cancer patients.
Varian has secured an IDE approval from the US Food and Drug Administration (FDA) to begin a clinical trial of FLASH therapy.
Comments are closed.